Research ExplorerPublicationsHypothalamic-pituitary-adrenocortical axis activity: a targe...

Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?

Standard

Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? / Kiefer, Falk; Jahn, Holger; Otte, Christian; Naber, Dieter; Wiedemann, Klaus.

In: BIOL PSYCHIAT, Vol. 60, No. 1, 1, 2006, p. 74-76.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kiefer, F, Jahn, H, Otte, C, Naber, D & Wiedemann, K 2006, 'Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?', BIOL PSYCHIAT, vol. 60, no. 1, 1, pp. 74-76. <http://www.ncbi.nlm.nih.gov/pubmed/16483549?dopt=Citation>

APA

Kiefer, F., Jahn, H., Otte, C., Naber, D., & Wiedemann, K. (2006). Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? BIOL PSYCHIAT, 60(1), 74-76. [1]. http://www.ncbi.nlm.nih.gov/pubmed/16483549?dopt=Citation

Vancouver

Kiefer F, Jahn H, Otte C, Naber D, Wiedemann K. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? BIOL PSYCHIAT. 2006;60(1):74-76. 1.

Bibtex

@article{964477b5e9e94a448a308588222453e5,
title = "Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?",
abstract = "BACKGROUND: An association between the activity of the hypothalamic-pituitary-adrenocortical (HPA) axis and alcohol intake behavior is currently discussed. We examined the relationship between efficacy of pharmacological anticraving treatment and HPA axis activity in the relapse prevention treatment of alcoholism. METHODS: In 160 patients suffering from alcoholism, we measured plasma adrenocorticotropic hormone (ACTH) and cortisol during placebo-controlled relapse prevention treatment with naltrexone and/or acamprosate. RESULTS: In the placebo group, ACTH and cortisol decreased during early abstinence. Treatment with naltrexone and acamprosate prevented this course. Increased ACTH and cortisol during treatment was associated with a reduced risk of relapse. CONCLUSIONS: These findings suggest that heightened HPA responsiveness might contribute to relapse-preventing effects of anticraving compounds in alcoholism.",
author = "Falk Kiefer and Holger Jahn and Christian Otte and Dieter Naber and Klaus Wiedemann",
year = "2006",
language = "Deutsch",
volume = "60",
pages = "74--76",
journal = "BIOL PSYCHIAT",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

RIS

TY - JOUR

T1 - Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?

AU - Kiefer, Falk

AU - Jahn, Holger

AU - Otte, Christian

AU - Naber, Dieter

AU - Wiedemann, Klaus

PY - 2006

Y1 - 2006

N2 - BACKGROUND: An association between the activity of the hypothalamic-pituitary-adrenocortical (HPA) axis and alcohol intake behavior is currently discussed. We examined the relationship between efficacy of pharmacological anticraving treatment and HPA axis activity in the relapse prevention treatment of alcoholism. METHODS: In 160 patients suffering from alcoholism, we measured plasma adrenocorticotropic hormone (ACTH) and cortisol during placebo-controlled relapse prevention treatment with naltrexone and/or acamprosate. RESULTS: In the placebo group, ACTH and cortisol decreased during early abstinence. Treatment with naltrexone and acamprosate prevented this course. Increased ACTH and cortisol during treatment was associated with a reduced risk of relapse. CONCLUSIONS: These findings suggest that heightened HPA responsiveness might contribute to relapse-preventing effects of anticraving compounds in alcoholism.

AB - BACKGROUND: An association between the activity of the hypothalamic-pituitary-adrenocortical (HPA) axis and alcohol intake behavior is currently discussed. We examined the relationship between efficacy of pharmacological anticraving treatment and HPA axis activity in the relapse prevention treatment of alcoholism. METHODS: In 160 patients suffering from alcoholism, we measured plasma adrenocorticotropic hormone (ACTH) and cortisol during placebo-controlled relapse prevention treatment with naltrexone and/or acamprosate. RESULTS: In the placebo group, ACTH and cortisol decreased during early abstinence. Treatment with naltrexone and acamprosate prevented this course. Increased ACTH and cortisol during treatment was associated with a reduced risk of relapse. CONCLUSIONS: These findings suggest that heightened HPA responsiveness might contribute to relapse-preventing effects of anticraving compounds in alcoholism.

M3 - SCORING: Zeitschriftenaufsatz

VL - 60

SP - 74

EP - 76

JO - BIOL PSYCHIAT

JF - BIOL PSYCHIAT

SN - 0006-3223

IS - 1

M1 - 1

ER -